Literature DB >> 14500363

Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene.

Wenbin Ma1, Lino Tessarollo, Seung-Beom Hong, Masaya Baba, Eileen Southon, Timothy C Back, Sally Spence, Corrinne G Lobe, Nirmala Sharma, Gregory W Maher, Svetlana Pack, Alexander O Vortmeyer, Chuanfa Guo, Berton Zbar, Laura S Schmidt.   

Abstract

von Hippel-Lindau (VHL) disease is a multisystem inherited cancer syndrome characterized by the development of highly vascular tumors including hemangioblastomas of the retina and central nervous system, pheochromocytomas, and clear cell renal carcinoma, which result from somatic inactivation of the wild-type VHL allele in cells harboring a germ-line VHL mutation. Homozygous inactivation of the VHL gene in mice resulted in embryonic lethality. To produce a mouse model that closely mimics human VHL disease and avoids embryonic lethality, we used Cre/lox site-specific recombination technology. We generated mice carrying conditional VHL alleles and a cre transgene under the control of the human beta-actin promoter, which directs cre expression in a mosaic pattern in multiple organs. VHL(f/d)/Cre mice developed multiple, hepatic hemangiomas that led to premature death, as well as angiectasis and angiogenesis in multiple organs. Interestingly, testes of male VHL(f/d)/Cre mice were unusually small with severely reduced sperm count resulting in infertility. Loss of pVHL function in this VHL conditional knockout mouse model results in an extensive abnormal vascular phenotype in multiple mouse organs, which will provide a useful animal model for testing potential antiangiogenic therapies for VHL disease treatment. Importantly, the phenotypic defects in sperm development observed in these mice support a novel role for VHL in spermatogenesis. This VHL conditional knockout mouse model will provide an in vivo system for studying the functional requirement of the VHL gene in reproductive biology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500363

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo.

Authors:  William Y Kim; Michal Safran; Marshall R M Buckley; Benjamin L Ebert; Jonathan Glickman; Marcus Bosenberg; Meredith Regan; William G Kaelin
Journal:  EMBO J       Date:  2006-09-14       Impact factor: 11.598

2.  Deletion of the von Hippel-Lindau Gene in Hemangioblasts Causes Hemangioblastoma-like Lesions in Murine Retina.

Authors:  Herui Wang; Matthew J Shepard; Chao Zhang; Lijin Dong; Dyvon Walker; Liliana Guedez; Stanley Park; Yujuan Wang; Shida Chen; Ying Pang; Qi Zhang; Chun Gao; Wai T Wong; Henry Wiley; Karel Pacak; Emily Y Chew; Zhengping Zhuang; Chi-Chao Chan
Journal:  Cancer Res       Date:  2018-01-04       Impact factor: 12.701

3.  Conditional ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for cell survival and mouse skin tumorigenesis.

Authors:  E Sterneck; S Zhu; A Ramirez; J L Jorcano; R C Smart
Journal:  Oncogene       Date:  2006-02-23       Impact factor: 9.867

4.  U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia.

Authors:  W Xiao; Q Zhang; G Habermacher; X Yang; A-Y Zhang; X Cai; J Hahn; J Liu; M Pins; L Doglio; R Dhir; J Gingrich; Z Wang
Journal:  Oncogene       Date:  2007-09-17       Impact factor: 9.867

5.  Acute inactivation of the VHL gene contributes to protective effects of ischemic preconditioning in the mouse kidney.

Authors:  Mitsuko Iguchi; Yoshihiko Kakinuma; Atsushi Kurabayashi; Takayuki Sato; Taro Shuin; Seung-Beom Hong; Laura S Schmidt; Mutsuo Furihata
Journal:  Nephron Exp Nephrol       Date:  2008-10-27

Review 6.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

7.  Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein.

Authors:  Li Lei; Steve Mason; Dinggang Liu; Yan Huang; Carolyn Marks; Reed Hickey; Ion S Jovin; Marc Pypaert; Randall S Johnson; Frank J Giordano
Journal:  Mol Cell Biol       Date:  2008-02-19       Impact factor: 4.272

8.  A Comprehensive Study of Progressive Cytogenetic Alterations in Clear Cell Renal Cell Carcinoma and a New Model for ccRCC Tumorigenesis and Progression.

Authors:  Zhongfa Zhang; Bill Wondergem; Karl Dykema
Journal:  Adv Bioinformatics       Date:  2010-07-05

9.  VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.

Authors:  C M Lee; M M Hickey; C A Sanford; C G McGuire; C L Cowey; M C Simon; W K Rathmell
Journal:  Oncogene       Date:  2009-03-02       Impact factor: 9.867

10.  Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations.

Authors:  H-C Jennifer Shen; Asha Adem; Kris Ylaya; Arianne Wilson; Mei He; Dominique Lorang; Stephen M Hewitt; Klaus Pechhold; David M Harlan; Irina A Lubensky; Laura S Schmidt; W Marston Linehan; Steven K Libutti
Journal:  PLoS One       Date:  2009-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.